Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
20
VRAX Quote, Financials, Valuation and Earnings
Last price:
$0.17
Seasonality move
:
-34.96%
Day range:
$0.16 - $0.21
52-week range:
$0.15 - $1.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
230.71x
P/B ratio:
0.60x
Volume:
2.3M
Avg. volume:
8.5M
1-year change:
-84.74%
Market cap:
$994.8K
Revenue:
$6.3K
EPS (TTM):
-$1.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VRAX
Virax Biolabs Group Ltd.
|
$1K | -$0.07 | -- | -- | $1.00 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $7.02 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -- | -- | -- |
|
SLNCF
Silence Therapeutics Plc
|
$2.1M | -$0.15 | 1346.55% | -12.5% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VRAX
Virax Biolabs Group Ltd.
|
$0.17 | $1.00 | $994.8K | -- | $0.00 | 0% | 230.71x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$0.87 | $7.02 | $1.1M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$1.63 | $104.00 | $7.2M | -- | $0.00 | 0% | -- |
|
OXBDF
Oxford Biomedica Plc
|
$7.03 | -- | $849.9M | -- | $0.00 | 0% | 3.58x |
|
SLNCF
Silence Therapeutics Plc
|
$2.00 | -- | $283.4M | -- | $0.00 | 0% | 506.96x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VRAX
Virax Biolabs Group Ltd.
|
-- | 0.532 | -- | 10.54x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 2.575 | -- | 1.20x |
|
NCNA
NuCana Plc
|
2.7% | 1.400 | 6.07% | 5.06x |
|
OXBDF
Oxford Biomedica Plc
|
37.49% | 3.140 | -- | 1.99x |
|
SLNCF
Silence Therapeutics Plc
|
0.26% | 2.446 | 0.06% | 6.25x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VRAX
Virax Biolabs Group Ltd.
|
-- | -- | -100.4% | -100.4% | -- | -- |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$91.8K | -$3.8M | -211.1% | -215.21% | -- | -$1.3M |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -90.47% | -120.93% | -- | -- |
|
SLNCF
Silence Therapeutics Plc
|
-$79K | -$12.6M | -94.14% | -94.26% | -37150% | -$16.7M |
Virax Biolabs Group Ltd. vs. Competitors
-
Which has Higher Returns VRAX or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Virax Biolabs Group Ltd.'s net margin of --. Virax Biolabs Group Ltd.'s return on equity of -100.4% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital VRAXVirax Biolabs Group Ltd.-- -- $8.4M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About VRAX or BDRX?
Virax Biolabs Group Ltd. has a consensus price target of $1.00, signalling upside risk potential of 474.71%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $7.02 which suggests that it could grow by 704.13%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Virax Biolabs Group Ltd., analysts believe Biodexa Pharmaceuticals Plc is more attractive than Virax Biolabs Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings VRAXVirax Biolabs Group Ltd.1 0 0 BDRXBiodexa Pharmaceuticals Plc0 0 0 -
Is VRAX or BDRX More Risky?
Virax Biolabs Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.106, suggesting its more volatile than the S&P 500 by 10.59%.
-
Which is a Better Dividend Stock VRAX or BDRX?
Virax Biolabs Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virax Biolabs Group Ltd. pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRAX or BDRX?
Virax Biolabs Group Ltd. quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Virax Biolabs Group Ltd.'s net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Virax Biolabs Group Ltd.'s price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virax Biolabs Group Ltd. is 230.71x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRAXVirax Biolabs Group Ltd.230.71x -- -- -- BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns VRAX or NCNA?
NuCana Plc has a net margin of -- compared to Virax Biolabs Group Ltd.'s net margin of --. Virax Biolabs Group Ltd.'s return on equity of -100.4% beat NuCana Plc's return on equity of -215.21%.
Company Gross Margin Earnings Per Share Invested Capital VRAXVirax Biolabs Group Ltd.-- -- $8.4M NCNANuCana Plc-- -$0.80 $33.6M -
What do Analysts Say About VRAX or NCNA?
Virax Biolabs Group Ltd. has a consensus price target of $1.00, signalling upside risk potential of 474.71%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 1275973.62%. Given that NuCana Plc has higher upside potential than Virax Biolabs Group Ltd., analysts believe NuCana Plc is more attractive than Virax Biolabs Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings VRAXVirax Biolabs Group Ltd.1 0 0 NCNANuCana Plc0 1 0 -
Is VRAX or NCNA More Risky?
Virax Biolabs Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.791, suggesting its more volatile than the S&P 500 by 79.145%.
-
Which is a Better Dividend Stock VRAX or NCNA?
Virax Biolabs Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virax Biolabs Group Ltd. pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRAX or NCNA?
Virax Biolabs Group Ltd. quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Virax Biolabs Group Ltd.'s net income of -- is lower than NuCana Plc's net income of -$3.3M. Notably, Virax Biolabs Group Ltd.'s price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virax Biolabs Group Ltd. is 230.71x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRAXVirax Biolabs Group Ltd.230.71x -- -- -- NCNANuCana Plc-- -- -- -$3.3M
-
Which has Higher Returns VRAX or OXBDF?
Oxford Biomedica Plc has a net margin of -- compared to Virax Biolabs Group Ltd.'s net margin of --. Virax Biolabs Group Ltd.'s return on equity of -100.4% beat Oxford Biomedica Plc's return on equity of -120.93%.
Company Gross Margin Earnings Per Share Invested Capital VRAXVirax Biolabs Group Ltd.-- -- $8.4M OXBDFOxford Biomedica Plc-- -- $140.3M -
What do Analysts Say About VRAX or OXBDF?
Virax Biolabs Group Ltd. has a consensus price target of $1.00, signalling upside risk potential of 474.71%. On the other hand Oxford Biomedica Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Virax Biolabs Group Ltd. has higher upside potential than Oxford Biomedica Plc, analysts believe Virax Biolabs Group Ltd. is more attractive than Oxford Biomedica Plc.
Company Buy Ratings Hold Ratings Sell Ratings VRAXVirax Biolabs Group Ltd.1 0 0 OXBDFOxford Biomedica Plc0 0 0 -
Is VRAX or OXBDF More Risky?
Virax Biolabs Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oxford Biomedica Plc has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.298%.
-
Which is a Better Dividend Stock VRAX or OXBDF?
Virax Biolabs Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oxford Biomedica Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virax Biolabs Group Ltd. pays -- of its earnings as a dividend. Oxford Biomedica Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRAX or OXBDF?
Virax Biolabs Group Ltd. quarterly revenues are --, which are smaller than Oxford Biomedica Plc quarterly revenues of --. Virax Biolabs Group Ltd.'s net income of -- is lower than Oxford Biomedica Plc's net income of --. Notably, Virax Biolabs Group Ltd.'s price-to-earnings ratio is -- while Oxford Biomedica Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virax Biolabs Group Ltd. is 230.71x versus 3.58x for Oxford Biomedica Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRAXVirax Biolabs Group Ltd.230.71x -- -- -- OXBDFOxford Biomedica Plc3.58x -- -- --
-
Which has Higher Returns VRAX or SLNCF?
Silence Therapeutics Plc has a net margin of -- compared to Virax Biolabs Group Ltd.'s net margin of -34617.65%. Virax Biolabs Group Ltd.'s return on equity of -100.4% beat Silence Therapeutics Plc's return on equity of -94.26%.
Company Gross Margin Earnings Per Share Invested Capital VRAXVirax Biolabs Group Ltd.-- -- $8.4M SLNCFSilence Therapeutics Plc-232.35% -$0.08 $62.5M -
What do Analysts Say About VRAX or SLNCF?
Virax Biolabs Group Ltd. has a consensus price target of $1.00, signalling upside risk potential of 474.71%. On the other hand Silence Therapeutics Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Virax Biolabs Group Ltd. has higher upside potential than Silence Therapeutics Plc, analysts believe Virax Biolabs Group Ltd. is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings VRAXVirax Biolabs Group Ltd.1 0 0 SLNCFSilence Therapeutics Plc1 0 0 -
Is VRAX or SLNCF More Risky?
Virax Biolabs Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Silence Therapeutics Plc has a beta of 0.736, suggesting its less volatile than the S&P 500 by 26.378%.
-
Which is a Better Dividend Stock VRAX or SLNCF?
Virax Biolabs Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Silence Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virax Biolabs Group Ltd. pays -- of its earnings as a dividend. Silence Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRAX or SLNCF?
Virax Biolabs Group Ltd. quarterly revenues are --, which are smaller than Silence Therapeutics Plc quarterly revenues of $34K. Virax Biolabs Group Ltd.'s net income of -- is lower than Silence Therapeutics Plc's net income of -$11.8M. Notably, Virax Biolabs Group Ltd.'s price-to-earnings ratio is -- while Silence Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virax Biolabs Group Ltd. is 230.71x versus 506.96x for Silence Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRAXVirax Biolabs Group Ltd.230.71x -- -- -- SLNCFSilence Therapeutics Plc506.96x -- $34K -$11.8M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
